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Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease and still continues to have the
worst prognosis of all gastrointestinal malignancies. Reports have demonstrated that secretory leukocyte protease
inhibitor (SLPI) is overexpressed in various cancers and may be a potential therapeutic strategy for the treatment of
different cancers. However, the possible role of SLPI in PDAC is still unknown. In the present study, we investigate
the effects of SLPI gene knockdown on the biological behavior of human pancreatic cancer cells. The expressions
of SLPI were detected, by qRT-PCR and Western blot, in human PDAC tissues as well as AsPC-1, BxPC-3 and PANC-1
cells. After transfection with siRNA targeting to SLPI, SLPI expression was detected by qRT-PCR and Western blot in
cells. Cell proliferation and apoptosis were also evaluated by MTT assay and flow cytometry (FCM). The trans-well
assays were also employed to explore the effects of SLPI knockdown on the migration and invasion of PDAC cells in vitro.
Results: The expressions of SLPI derived from human PDAC and PDAC cell lines were significant higher than those of
control groups, respectively (P < 0.05). Regression analysis showed elevated SLPI level was positive correlated with
development of PDAC. The siRNA target to SLPI significantly decreased the expressions of SLPI in these PDAC cell lines.
Following SLPI-siRNA transduction, the proliferative capacity of the AsPC-1, BxPC-3 and PANC-1 cells was significantly
inhibitions, compared to the blank (PDAC-wild type cells) and negative (non-targeting scrambled siRNA transduced PDAC
cells) control ones, respectively (P < 0.05). Moreover, SLPI knockdown significantly increased the apoptosis fractions and
reduced the migration and invasion of PDAC cells in vitro (P < 0.05).
Conclusions: The present study demonstrated that: i) SLPI played an important role in PDAC progression; ii) SLPI might
be an important characteristic of malignant PDAC associated with migration and invasion in vitro; and iii) siRNA targeting
to SLPI might be a potential therapeutic strategy for the treatment of PCC.
Keywords: Pancreatic ductal adenocarcinoma, Secretory leukocyte protease inhibitor, Small interference RNA, Cell
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Pancreatic ductal adenocarcinoma (PDAC) accounts for
95% of pancreatic cancer (PCC) and has a dismal prog-
nosis, with only a 6% 5-year survival rate [1]. Despite
considerable advances in radiological techniques, it often
presents as a locally advanced or metastatic disease in
most patients and only about 10-20% of patients are
considered candidate to surgery [2]. Unfortunately, most
of the patients with PDAC are diagnosed at an advanced
stage due to the lack of obvious symptoms, and their
prognosis remains very dismal [3,4]. Thus, early* Correspondence: zhangwei_weinan@126.com
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unless otherwise stated.detection and diagnosis of PDAC still present the best
chance for successful treatments and improved outcomes.
Secretory leukocyte protease inhibitor (SLPI) is
present in human mucus secretions and tissues and pro-
duced primarily in the epithelial cells lining the respira-
tory, digestive and reproductive tracts [5,6]. SLPI,
11.7 kDa serine protease inhibitor, is belongs to the
whey acidic protein four-disulfide core family of
proteins. It binds heparin, a highly sulfated glycosamino-
glycan also found in mast cell secretary granules, and
the interaction increases its effectiveness as an inhibitor
of neutrophil elastase [7]. SLPI was reported to be an
anti-inflammatory factor that contributes at the early in-
flammatory response in odontoblasts [8]. In addition,
SLPI was reported to play a role not only in protecting theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biting HIV infections, anti-bacterial and anti-fungal
activity [9-11]. Gene-targeting experiments in mice in-
dicated that one function of SLPI is to protect proe-
pithelin from elastase cleavage in wound healing.
Recent study showed that SLPI expression in relation
to cancer progression, metastasis and invasion [5,12].
SLPI is also produced in cancer tissues and upregulated
under tumorigenic conditions. It is often elevated in
various cancer tissues including lung, head/neck and
ovarian cancers [6]. However, its role in cancer is not
well understood, especially in PDAC.
The present study aimed to investigate the impact of
SLPI gene knockdown on the biological behavior of human
PDAC cells. The expressions of SLPI were detected, by
quantity real-time PCR (qRT-PCR) and Western blot, in
human PDAC tissues, adjacent normal tissues and human
PDAC AsPC-1, BxPC-3 and PANC-1 cell lines. Then, an
expressional knockdown vector carrying a small interfer-
ence RNA (siRNA) targeting the SLPI gene was con-
structed and transfected into these cells. After transfection,
SLPI expressions were detected by qRT-PCR and Western
blot. The cell proliferation and apoptosis fractions were also
evaluated by MTT assay and flow cytometry (FCM). The
trans-well assays were also employed to explore the effects
of SLPI knockdown on the migration and invasion of
PDAC cells in vitro.
Results
SLPI expression in PDAC and normal tissues
The patients ranged in age from 47 to 69 years, with a me-
dian age of 56 years. SLPI expression was lowest among
health normal tissue and significantly increased in PDAC
patients (chi2=14.73, P < 0.05). Those patients determined
higher levels of SLPI in PDAC samples increased the risk of
high pathological type (P < 0.05).
SLPI elevated in human PDAC tissues and cells
SLPI staining in normal adjacent tissue was weak relative to
PDAC tissues. The IHC positive files of SLPI exhibited light
yellow to brown staining (Figure 1A). Either qRT-PCR or
Western blot analysis showed that the expressions of SLPI
in PDAC tissue were significantly intensive than that of
normal adjacent tissues (P < 0.05, Figure 1B and C).
Compared with that of normal human pancreas
hTERT-HPNE cells, the mRNA and protein levels of
SLPI in AsPC-1, BxPC-3 and PANC-1 increased signifi-
cantly (P < 0.05, Figure 1B and C).
Special SLPI target siRNA transduction induced inhibitions
of SLPI
Stable expression of three SLPI siRNA (si-1, si-2, si-3
and si-4) in PDAC cells resulted in >75% decrease in
SLPI expression (Figure 2A-D). Considering the highestexpressional inhibition rates in SLPI, si-3 was chosen as
the target siRNA for followed investigation.
The PDAC cell lines, including AsPC-1, BxPC-3 and
PANC-1 cells, then were stably transfected with SLPI si-3
(named as AsPC-1-SLPI-si, BxPC-3-SLPI-si and PANC-1-
SLPI-si, respectively). Negative control AsPC-1, BxPC-3
and PANC-1 cells were transfected with non-targeting
siRNA vectors. They were recorded as AsPC-1-Non, BxPC-
3-Non and PANC-1-Non, respectively. The wild type
PDAC cells were also employed as the blank control, which
was named as AsPC-1-WT, BxPC-3-WTand PANC-1-WT,
respectively. SLPI mRNA levels detected by qRT-PCR were
significantly lower in SLPI-siRNA expressed cells than the
matched control ones (P < 0.05, Figure 2E). Western blot
analysis found that the level of immunoreactive protein was
significantly down-regulated in SLPI-siRNA transfected
cells relative to the controls cells (P < 0.05, Figure 2G).
Effects of SLPI-siRNA on PDAC cells proliferation
We assessed the effect of SLPI expressional silence on
the regulation of PDAC cells viability. MTT assay
showed that SLPI expressional knockdown caused
significantly decrease in cell viability in AsPC-1, BxPC-3
and PANC-1 cells, compared with that of the control
ones, respectively (P < 0.05, Figure 3A, B and C).
SLPI knockdown induced increase apoptosis of PDAC cells
There was a significant increase in the apoptosis rate in
SLPI-siRNA infected cells relative to Empty infected
ones detected by FCM (Figure 4). There were more
apoptosis PDAC cells in AsPC-1-SLPI-siRNA, BxPC-3-
SLPI-siRNA and PANC-1-SLPI-siRNA groups, when
compared with that of the matched WT and non-
targeting siRNA control groups, respectively (P < 0.05,
Figure 4A and B).
Effect of SLPI knockdown on PDAC cell migration
Following knockdown, we compared the migration of con-
trol non-transduced innocent cells (blank), non-targeting
scrambled siRNA transduced cells (negative control), as
well as the SLPI knockdown cells transduced with SLPI tar-
geting siRNA. The migration assay showed that the crystal
violet stained cells significantly decreased in the SLPI-
siRNA treated cells, compared with that of the matched
WT and non-targeting siRNA control groups (P < 0.01,
Figure 5A). The SLPI knockdown treatment significantly
decreased the migration of the three cell types compared to
the negative and blank control ones. Through the
whole experimental duration, migration was not
significantly different between AsPC-1, BxPC-3 and
PANC-1 blank cells and the negative control cells
transduced with non targeting scrambled siRNA, as
shown in Figure 5A.
Figure 1 IHC positive staining of SLPI in PDAC tissues and cell lines. PDAC, pancreatic ductal adenocarcinoma tissue. A, Representative IHC
files of SLPI in normal adjacent (up) and PDAC tissue (down) There is more intense yellow or yellow-brown staining for SLPI in PDAC tissue than
that in normal adjacent tissue. B, the quantities analysis of relative mRNA levels of SLPI in PDAC tissue and cells. C, the representative immunoblotting
photograph and the quantities analysis of protein levels of SLP. The arrow shows the representative immunostaining of SLPI. Magnification: x 200. Values
plotted are means ± SD (n=45).
Zhang et al. Cancer Cell International  (2015) 15:37 Page 3 of 10
Figure 2 (See legend on next page.)
Zhang et al. Cancer Cell International  (2015) 15:37 Page 4 of 10
(See figure on previous page.)
Figure 2 Expressions of SLPI in various cell lines after SLPI-siRNA transduction. A, the protein expressions of SLPI were evaluated by
Western blot following SLPI knockdown by siRNA transfection. B, C and D, the quantities analysis of relative protein levels of SLPI after SLPI-siRNA
treatment in three PDAC cell lines. GAPDH was used as the control. Considering the highest expressional inhibition rates in SLPI, si-3 was chosen
as the target siRNA for followed investigation. E, relative SLPI mRNA levels detected by qRT-PCR were significantly lower in SLPI-siRNA expressed
AsPC-1, BxPC-3 and PANC-1cells than the matched control (PDAC-WT or PDAC-Non), respectively (P < 0.05). F, the immunoblotting analysis of SLPI
following SLPI knockdown. G, the quantities analysis of relative protein levels of SLPI after SLPI-siRNA treatment in three PDAC cell lines. Values
plotted are means ± SD (n=3). * vs PDAC-WT cell lines, P < 0.05. # vs PDAC-Non cell lines, P < 0.05.
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There were significant reductions in the invasion of
AsPC-1, BxPC-3 and PANC-1 cells following SLPI
knockdown, in comparison with that of the control
cells, respectively (P < 0.005) (Figure 5B). The invasion
of control cells transduced with non-targeting siRNA,
which had unchanged levels of SLPI, was not
significantly different from the non-transduced WT
PDAC cells.Figure 3 Effects of SLPI on PDAC cell proliferation. MTT assay time-cou
cells (C). After SLPI down-regulation, AsPC-1 cells and PANC-1cells showed
ones (negative and blank control), respectively (P < 0.05). Values plotted are
cell lines, P < 0.05.Discussion
The current study showed that SLPI elevated in human
PDAC tissue and cell lines, including AsPC-1, BxPC-3
and PANC-1 cells. Increased expression of SLPI was
positively correlated with the PDAC development. Target
SLPI-siRNA transduction in AsPC-1, BxPC-3 and PANC-1
cells induced: i) significant inhibitions in proliferation; ii)
increase apoptosis fractions; and iii) the reductions of mi-
gration and invasion of PDAC cells. These data suggestedrse for WT and SLPI-silence AsPC-1 cells (A), BxPC-3 (B) and PANC-1
significant decrease in proliferation compared with that of control
means ± SD (n=3). * vs PDAC-WT cell lines, P < 0.05. # vs PDAC-Non
Figure 4 SLPI knockdown induced apoptosis in PCC cells. A, the influences of SLPI knockdown on the apoptosis of AsPC-1 cells, BxPC-3 and
PANC-1 were detected by FCM, respectively. B, quantification shows that the percentage of apoptotic cells in SLPI-siRNA transfected group is significantly
higher compared to that in the control groups. Values plotted are means ± SD (n=3). * vs PDAC-WT cell lines, P< 0.05. # vs PDAC-Non cell lines, P< 0.05.
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sion, and siRNA targeting of SLPI might be a potential
therapeutic strategy for the treatment of PDAC.
It is well established that SLPI protects tissue from
proteases, and promotes cell proliferation and healing
during inflammatory response. In replicated proteomicdatasets, the SLPI protein stood out based on its de-
crease in abundance in both oral premalignant lesion tis-
sue (OPMLs) and oral squamous cell carcinoma (OSCC)
lesion tissues compared to healthy normal tissue [13]. By
multiplex proximity ligation assay, Simon Fredriksson et al.
had demonstrated that SLPI was overexpressed in plasma
Figure 5 The effects of SLPI knockdown on the migration and invasion of PDAC cell lines. A, migration was expressed as number of
migrating cells per 40X field. B, Invasion was expressed as number of invading cells per 40X field. Values plotted are means ± SD (n=3). * vs
PDAC-WT cell lines, P < 0.05. # vs PDAC-Non cell lines, P < 0.05.
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controls, and in behaved as high-abundance markers for
pancreatic cancer [14]. In the present, we found that the
mRNA and protein levels of SLPI were significantly
unregulated in human PDAC tissue and PDAC cell lines,
AsPC-1, BxPC-3 and PANC-1 cells. Following target SLPI-
siRNA transduction, cell proliferation of AsPC-1, BxPC-3
and PANC-1 cells was significantly inhibited, which
was coincident with the increase apoptosis fractions.
These facts suggested that SLPI might play a critical
role in the progression of tumor growth and prolifera-
tion in human PDAC.
Moreover, our data also revealed that SLPI knockdown
lead significant reduction in migration and invasion of
PDAC cells, which might indicate an import role of SLPI
involved in metastasis of PDAC. Recent reports revealed
that SLPI is also overexpressed in gastric, lung and ovar-
ian cancers, which accelerates the metastasis of cancercells. The overexpression of SLPI was involved in
metastasis of lung carcinoma 3LL-S cells [15]. Other
researches showed that SLPI, expressed in a range of
cancer cell lines, was particularly overexpressed in the
highly liver metastatic tumor [16]. It is also revealed
SLPI is overexpressed in rarely developed inflammatory
breast cancer with highly angiogenic and metastatic
capacity [17]. Additionally, the overexpression of SLPI in
lung carcinoma cells showed rapid tumorigenicity and
lung metastasis upon subcutaneous inoculation com-
pared to the control cells [15]. Moreover, the blood con-
centration of SLPI was high in ovarian cancer compared
to normal ovaries or benign ovarian tumors, and is par-
ticularly high in malignant tumors with a high metastatic
potential [18]. It also demonstrated that SLPI mRNA
was overexpressed in serosa invading gastric cancer cells,
and the cell migration and invasion rate was significantly
increased in a SLPI overexpressing gastric cancer cell
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that SLPI might be associated with the metastatic poten-
tial of malignant PDAC and a potential therapeutic
target. However, the mechanism underlying still needed
further investigations.
Conclusions
In conclusion, the present results showed that SLPI was
overexpressed in human PDAC tissues and PDAC cell
lines. SLPI knockdown by target siRNA introduction
induced significantly inhibitions in proliferative capacity,
increase in apoptosis, and reductions of migration and
invasion of AsPC-1, BxPC-3 and PANC-1 cells. These
findings suggested that: i) SLPI played an important role
in PDAC progression; ii) SLPI might be an important
characteristic of malignant PDAC associated with migra-
tion and invasion in vitro; and iii) siRNA targeting to




Through the surgery consent form, patients were in-
formed that the resected specimens were kept by our
hospital and might be used for scientific research, and
that their privacy would be maintained.
Forty-five patients attending the clinic in the central
Hospital of Weinan City in Shanxi Province, between
February/2013 to May/2014, were invited to participate
in the study. The patients ranged in age from 46 to 75 years,
with a median age of 54 years. All of them accepted the
operation for the first time, without any anti-tumor treat-
ment. The specimens were histopathologically verified as
PDAC by senior pathologists. Then the tumor samples and
matched normal adjacent tissues were obtained, which
were taken at least 0.5 cm distal to tumor margins. The
biopsies obtained were divided into two fragments immedi-
ately after surgery. One fragment was immediately stored at
−80°C until nucleic acids and proteins isolation. The
remaining fragment was fixed in 4% formaldehyde for two
days and then was paraffin-embedded. The paraffin blocks
were sliced and stained with immunohistochemistry (IHC)
for histological examination.
IHC staining
Immunohistochemistry was performed to determine the
SLPI expression in normal adjacent tissue and PCC tis-
sues, as described followed. Briefly, tumor samples and
the matched control tissues were fixed in 4% formalde-
hyde, embedded in paraffin wax, and then cut into 4 μm
sections using a microtome. These frozen sections were
incubated with 2% goat serum at 37°C for 20 min,
followed by incubation with goat-anti-human SLPI
(1:500, Santa cruz, sc-10535) at 4°C overnight. Afterwashing with PBS, the sections were incubated with
horseradish peroxidase (HRP)-conjugated rabbit anti-rat
IgG (HRP-IgG) at 37°C for 30 min and colored with 3,
3′-Diaminobenzidine (DAB) at room temperature. PBS
was substituted for the anti-SLPI antibody in negative
control subjects.
Cell culture
Human PDAC cell lines AsPC-1, BxPC-3 and PANC-1,
as well as normal human pancreatic hTERT-HPNE cells
were purchased from Cell Bank of the Chinese Academy
of Sciences. All of these cells were cultured in specific
medium supplemented with 10% (v/v) fetal bovine
serum (FBS) and 1% antibiotics at 37°C in a humidified
incubator under 5% CO2 condition.
Quantitative reverse-transcription PCR
The expressions of SLPI in the PCC specimens and the
cell lines were detected by Quantitative real-time PCR
(qRT-PCR). Tumor samples (50 mg) were ground under
liquid nitrogen, lysed with 1 ml of Trizol (Takara, Japan),
and total RNA was extracted using Trizol (Invitrogen,
USA). Total RNA (2 μg) was added to the tumor
extract with Moloney Murine Leukemia Virus Reverse
Transcriptase (MMLV-RT, Takara, Japan) to synthesize
cDNA, and the reverse transcript was used as the tem-
plate for qRT-PCR using a Tower qRT-PCR system
(Analytic Jena, Germany). The qRT-PCR was conducted
using 2 ×Mix SYBR Green I (Biosea, USA) (10 μl), primer
(0.25 μl, 10 pmol/L), template DNA (1 μl), and sterile water
(8.5 μl). All PCR reactions included initial denaturation and
multiple cycles at (95°C for 3 min); 39 cycles at 95°C for
10 s, 54°C for 10 s, and 72°C for 30 s; followed by 95°C for
10 s, 65°C for 5 s, and a final 95°C for 15 s. The primer for
each gene was synthesized by Invitrogen (USA). The real
time PCR primers used to quantify GAPDH expres-
sion were: F: 5′-CGAGATCCCTCCAAAATCAA-3′
and R: 5′-TTCACACCCATGAC- GAACAT-3′ and for
SLPI were: F 5′-CCCTTCCTGGTGCTGCTT-3′ and
R: 5′- CCTCCTTGTTGGGTTTGG-3′. Expression of
SLPI was normalized to endogenous GAPDH expression.
Western blot
SLPI protein levels both in PDAC tissues and cell lines
were determined by Western blot. Briefly, samples were
lysed for 30 min in CytoBuster Protein Extraction Buffer
(Novagen, USA) and centrifuged at 12000 rpm. The
supernatant was collected, total protein was measured,
and 50 μg was used for 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The
protein was then transferred to a nitrocellulose (NC) mem-
brane and sealed with Tris-Buffered Saline Tween-20
(TBST) containing 5% non-fat milk powder. The mem-
brane was subsequently incubated with goat anti-human
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Santa cruz, sc-81545) at 4°C overnight. After washing in
TBST, the membrane was incubated with HPR conjugated
secondary antibodies (1:2000) at 25°C, and the protein
quantity was determined using electrochemiluminescence
(ECL) technique (BestBio, USA). The results were photo-
graphed using the JS Gel Imaging System (Peiqing, China)
and the grey density was calculated using SensiAnsys
software (Peiqing, China).
SLPI gene knockdown
According to the CDS of SLPI recorded in Neuclpeptide,
we predesigned small interference RNA (siRNA) targeting
the human SLPI gene (Gene ID, 10103) (http://RNAiDe
signer.invitrogen.com). The siRNA sequences targeting
SLPI are as follows. si-1: 5′-AAGCTGGAGTCTGTCC
TCCTAAGAA-3′, si-2: 5′-CAGTGCA- AGCGTGACTT
GAAGTGTT-3′, si-3: 5′-TCAAAGCTGGAGTCTGTCCT
CCTAA-3′, si-4: 5′-CAAAGCTGGAGTCTGTCCTCC
TAAG-3′. A scrambled non-target siRNA was also
used as a control. Lentivirus was packaging in 293 T
cells using Lipofectamine2000 (Invitrogen, Carlsbad,
CA) and virus titers were determined. The interference
efficiency of si-1-4 targeting SLPI in 293 T cells was
determined by qRT-PCR and Western blot. The target
siRNA was chosen for further investigation as it had
the highest interference efficiency. Then the cell lines
including AsPC-1, BxPC-3 and PANC-1 cells, were
then infected with 1 × 106 recombinant lentivirus-
transducing units containing the target siRNA or non-
targeting siRNA in the presence of 6 μg/ml polybrene
(Sigma), respectively.
Tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay
Cell viability was determined using the MTT assay.
Briefly, cells were plated into 96-well culture plates at an
optimal density of 5 × 103 cells/mL in 200 μL of culture
medium per well. After 24–96 h of culture, 20 μL of
5 mg/mL MTT was added to each well and incubated at
37°C for 4 h. The medium was then gently aspirated and
150 μL of dimethyl sulfoxide (DMSO) was added to each
well to solubilize the formazan crystals. The optical
density of each sample was immediately measured using
a microplate reader (BioRad, Hercules, CA, United
States) at 490 nm.
Apoptosis assay
A propidium iodide (PI) and annexin V-FITC-flow
cytometry assay (BD Pharmingen) was used to detect
the apoptosis rate in the cells after SLPI transfection.
Briefly, 1 × 106 cells per well were cultured in 6-well
plates in the absence of 10% FBS for 48 hours. Adherent
cells were detached with 0.25% trypsin without EDTA in1 × PBS. Cells were harvested in complete RPMI 1640
medium and centrifuged at 1000 rpm for 5 minutes.
Each of the cells were washed with 1 × PBS and stained
with 50 ug/ml PI and Annexin V-FITC, following the
manufacturer’s instructions.Cell migration and invasion assay
Biocoat matrigel invasion chambers (BD Biosciences,
Bedford, MA, United States) were used to compare the
effect of SLPI knockdown on in vitro invasion of AsPC-1,
BxPC-3 and PANC-1 cells as previously described [20,21].
Briefly, for the invasion assay, Costar Tran-swell 8 μm
inserts were coated with 50 μg reduced serum Matrigel
(BD Biosciences, Bedford, MA, United States). Invasion
Chambers (BD China, Shanghai, China) were coated
with Matrigel, and 1 × 106 cells were added per cham-
ber. Medium supplemented with 10% FBS was used in
the lower chamber. Following incubation cells that had
invaded through the membrane were fixed and stained
before the membrane was removed and mounted on a slide
for microscopic assessment. Invasive cells were visualized
at x40 magnification and the number of cells in five ran-
dom fields was counted and an average calculated.
For migration assays, the same procedure was used
excluding the Matrigel. After 12 h, non-invading cells
and media were removed, and cells on the lower surface
of the membrane were fixed with polyoxymethylene
(Sigma) and stained with 0.1% crystal violet (Sigma) for
0.5 h. Stained cells were counted under a microscope in
five randomly selected fields, and the average was used
to indicate cell migration and invasion. All experiments
were performed in triplicate [21].Statistical analysis
SPSS v11.5 (SPSS Inc., Chicago, IL) was used for statis-
tical analysis. Data are presented as means ± standard
deviation. Statistical significance was determined by the
t-test, One-way ANOVA analysis, followed by the Fisher
Halves test for other data analyses. A P < 0.05 was con-
sidered statistically significant.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
All authors participated in the design, interpretation of the studies and
analysis of the data and review of the manuscript. WZ, JLY and HPS were in
charge of clinical samples detections and collections. JLY, SCD, FQH and HPS
conducted the experiments. WZ and JLY carried out the cell lines cultured.
WZ and HPS wrote the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank the Labreal Bioscience and Technology Ltd. Company, Kunming,
China for its valuable contributions to parts of the experimental design and
conductions.
Zhang et al. Cancer Cell International  (2015) 15:37 Page 10 of 10Received: 30 August 2014 Accepted: 10 March 2015
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin.
2012;62(1):10–29.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.
3. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection
for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year
survivors. Ann Surg. 1996;223(3):273–9.
4. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363
(9414):1049–57.
5. Jan Treda C, Fukuhara T, Suzuki T, Nakamura A, Zaini J, Kikuchi T, et al.
Secretory leukocyte protease inhibitor modulates urethane-induced lung
carcinogenesis. Carcinogenesis. 2014;35(4):896–904.
6. Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T. Secretory leukocyte peptidase
inhibitor and lung cancer. Cancer Sci. 2008;99(5):849–55.
7. Walter M, Plotnick M, Schechter NM. Inhibition of human mast cell chymase
by secretory leukocyte proteinase inhibitor: enhancement of the interaction
by heparin. Arch Biochem Biophys. 1996;327(1):81–8.
8. Choi BD, Jeong SJ, Wang G, Kim HJ, Kim BO, Hwang HK, et al. Temporal
induction of secretory leukocyte protease inhibitor (SLPI) in odontoblasts by
lipopoly-saccharide and wound infection. J Endod. 2009;35:997–1002.
9. McKiernan PJ, McElvaney NG, Greene CM. SLPI and inflammatory lung
disease in females. Biochem Soc Trans. 2011;39(5):1421–6.
10. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission.
J Am Dent Assoc. 1998;129:851–8.
11. Sallenave JM. Antimicrobial activity of antiproteinases. Biochem Soc Trans.
2002;30:111–5.
12. Nishimura J, Saiga H, Sato S, Okuyama M, Kayama H, Kuwata H, et al. Potent
antimycobacterial activity of mouse secretory leukocyte protease
inhibitor. J Immunol. 2008;180(6):4032–9.
13. Yang Y, Rhodus NL, Ondrey FG, Wuertz BR, Chen X, Zhu Y, et al.
Quantitative proteomic analysis of oral brush biopsies identifies secretory
leukocyte protease inhibitor as a promising, mechanism-based oral cancer
biomarker. PLoS One. 2014;9(4):e95389.
14. Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC,
Tibshirani R, et al. Multiplexed proximity ligation assays to profile putative
plasma biomarkers relevant topancreatic and ovarian cancer. Clin Chem.
2008;54:582–9.
15. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte
protease inhibitor in cancer development. Ann NY Acad Sci. 2004;1028:380–9.
16. Morita M, Arakawa H, Nishimura S. Identifcation and cloning of a novel
isoform of mouse secretory leukocyte protease inhibitor, mSLPI-β, overexpressed
in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells. Adv
Enzyme Regul. 1999;33:341–55.
17. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B,
et al. Gene expression profling for molecular characterization of infammatory
breast cancer and prediction of response to chemotherapy. Cancer Res.
2004;64:8558–65.
18. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum
secretory leukocyte protease inhibitor levels in patients to improve
specifcity of ovarian cancer diagnosis. Gynecol Oncol. 2005;96:516–9.
19. Cheng WL, Wang CS, Huang YH, Liang Y, Lin PY, Hsueh C, et al.
Overexpression of a secretory leukocyte protease inhibitor in human gastric
cancer. Int J Cancer. 2008;123:1787–96.
20. Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M, et al.
In vitro cell migration and invasion assays. Mutat Res. 2013;752:10–24.
21. Sun GG, Wei CD, Jing SW, Hu WN. Interactions between filamin A and
MMP-9 regulate proliferation and invasion in renal cell carcinoma. Asian Pac
J Cancer Prev. 2014;15:3789–95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
